|Full HTA submission received from Applicant
|Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by HSE
|Pre-submission consultation with Applicant
|Full submission received from Applicant